OR WAIT null SECS
December 13, 2022
The approval is based on results from the pivotal EFFISAYIL 1 Phase II clinical trial.
mRNA-1273.222 has also received FDA EUA for children and adolescents between six and 17 years of age and for adults over the age of 18 years of age.
December 12, 2022
The guidance discusses statistical approaches for BE comparisons and focuses on how to use these approaches both generally and in specific situations.
December 07, 2022
One can improve method precision and productivity by replacing one step in sample preparation with an automated approach.
December 03, 2022
Unique solutions are required to protect inherently unstable messenger RNA.
November 29, 2022
The decision to move forward in Phase III development stems from the threat of resistance to current malaria treatment growth.
November 15, 2022
A look back at challenge and innovation highlights in 2022 for oral solid dosage forms, this podcast episode will review industry experts’ takes on factors driving the evolution of OSD forms as well as innovations in APIs, technology, and methodology.
November 03, 2022
Advancements in soft capsule technology can enable the development of soft capsule formulations, which are becoming the preferred method of oral administration.
High-concentration injectable formulations present unique challenges.
Opportunities and developments in particle engineering are providing developers with the tools to advance drug candidates successfully.